pyrazinamide has been researched along with AIDS Seroconversion in 17 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Excerpt | Relevance | Reference |
---|---|---|
" Peak drug exposure to isoniazid was lower in patients with diarrhea." | 3.69 | Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. ( Cameron, DW; Gallicano, K; Garber, G; Oliveras, L; Rachlis, A; Sahai, J; Seguin, I; Swick, L; Tailor, S; Walker, S, 1997) |
" We investigated the incidence of adverse events and cure rates according to HIV status for patients receiving standard TB therapy in the trial." | 2.90 | Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. ( Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; McHugh, TD; Mendel, CM; Meredith, SK; Mohapi, L; Murphy, ME; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD, 2019) |
"Optimum treatment of tuberculosis in persons with human immunodeficiency virus (HIV) infection is still being defined." | 2.38 | Failure of therapy for tuberculosis in human immunodeficiency virus infection. ( Nolan, CM, 1992) |
"Major adverse reactions to antituberculosis drugs can cause significant morbidity, and compromise treatment regimens for tuberculosis (TB)." | 1.32 | Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. ( Menzies, D; Parisien, I; Pelletier, M; Rocher, I; Valiquette, C; Yee, D, 2003) |
"Ethambutol was recovered from human urine quantitatively and stable for a period of at least one week in urine stored at -20 degrees C." | 1.32 | Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid. ( Bhagavathy, S; Gayathri, TN; Gurumurthy, P; Venkatesan, P, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 8 (47.06) | 18.2507 |
2000's | 3 (17.65) | 29.6817 |
2010's | 5 (29.41) | 24.3611 |
2020's | 1 (5.88) | 2.80 |
Authors | Studies |
---|---|
Tweed, CD | 1 |
Crook, AM | 2 |
Dawson, R | 1 |
Diacon, AH | 1 |
McHugh, TD | 3 |
Mendel, CM | 2 |
Meredith, SK | 2 |
Mohapi, L | 1 |
Murphy, ME | 1 |
Nunn, AJ | 3 |
Phillips, PPJ | 1 |
Singh, KP | 1 |
Spigelman, M | 1 |
Gillespie, SH | 3 |
Peetluk, LS | 1 |
Rebeiro, PF | 1 |
Cordeiro-Santos, M | 1 |
Kritski, A | 1 |
Andrade, BB | 1 |
Durovni, B | 1 |
Calvacante, S | 1 |
Arriaga, MB | 1 |
Turner, MM | 1 |
Figueiredo, MC | 1 |
Rolla, VC | 1 |
Sterling, TR | 1 |
Murray, SR | 1 |
Pappas, F | 1 |
Phillips, PP | 2 |
Jindani, A | 1 |
Harrison, TS | 1 |
Churchyard, GJ | 1 |
Charalambous, S | 1 |
Hatherill, M | 1 |
Geldenhuys, H | 1 |
McIlleron, HM | 1 |
Zvada, SP | 1 |
Mungofa, S | 1 |
Shah, NA | 1 |
Zizhou, S | 1 |
Magweta, L | 1 |
Shepherd, J | 1 |
Nyirenda, S | 1 |
van Dijk, JH | 1 |
Clouting, HE | 1 |
Coleman, D | 1 |
Bateson, AL | 1 |
Butcher, PD | 1 |
Mitchison, DA | 2 |
Khajotia, R | 1 |
Manthari, K | 1 |
Tripathy, S | 1 |
Anand, A | 1 |
Inamdar, V | 1 |
Manoj, MM | 1 |
Khillare, KM | 1 |
Datye, AS | 1 |
Iyer, R | 1 |
Kanoj, DM | 1 |
Thakar, M | 1 |
Kale, V | 1 |
Pereira, M | 1 |
Risbud, AR | 1 |
Chakaya, JM | 1 |
Kibuga, D | 1 |
Ng'ang'a, L | 1 |
Githui, WA | 1 |
Mansoer, JR | 1 |
Gakiria, G | 1 |
Kwamanga, D | 1 |
Maende, J | 1 |
Yee, D | 1 |
Valiquette, C | 1 |
Pelletier, M | 1 |
Parisien, I | 1 |
Rocher, I | 1 |
Menzies, D | 1 |
Gurumurthy, P | 1 |
Gayathri, TN | 1 |
Bhagavathy, S | 1 |
Venkatesan, P | 1 |
Kennedy, N | 1 |
Fox, R | 1 |
Kisyombe, GM | 1 |
Saruni, AO | 1 |
Uiso, LO | 1 |
Ramsay, AR | 1 |
Ngowi, FI | 1 |
Delaney, V | 1 |
Sumrani, N | 1 |
Hong, JH | 1 |
Sommer, B | 1 |
Kassim, S | 1 |
Sassan-Morokro, M | 1 |
Ackah, A | 1 |
Abouya, LY | 1 |
Digbeu, H | 1 |
Yesso, G | 1 |
Coulibaly, IM | 1 |
Coulibaly, D | 1 |
Whitaker, PJ | 1 |
Doorly, R | 1 |
Sahai, J | 1 |
Gallicano, K | 1 |
Swick, L | 1 |
Tailor, S | 1 |
Garber, G | 1 |
Seguin, I | 1 |
Oliveras, L | 1 |
Walker, S | 1 |
Rachlis, A | 1 |
Cameron, DW | 1 |
Nolan, CM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening[NCT00864383] | Phase 3 | 1,931 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
Using Biomarkers to Predict TB Treatment Duration[NCT02821832] | Phase 2 | 946 participants (Actual) | Interventional | 2017-06-21 | Active, not recruiting | ||
A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis[NCT04187469] | 286 participants (Anticipated) | Interventional | 2020-03-01 | Not yet recruiting | |||
Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789] | 555 participants (Actual) | Interventional | 2020-11-17 | Active, not recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The secondary analysis of efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome) based on MGIT. Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)
Intervention | participants with failure or relapse (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 65 |
Regimen 2 - 2MHRZ/2MHR | 98 |
Regimen 3 - 2EMRZ/2MR | 131 |
The primary efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome). Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. For the final 18 month study visit when both L-J samples were contaminated or missing, if the subject could not be brought back, liquid medium culture results were used in place of solid medium culture results. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)
Intervention | participants with failure or relapse (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 43 |
Regimen 2 - 2MHRZ/2MHR | 78 |
Regimen 3 - 2EMRZ/2MR | 105 |
Number of patients who are TB MGIT culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks
Intervention | participants who are culture negative (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 235 |
Regimen 2 - 2MHRZ/2MHR | 274 |
Regimen 3 - 2EMRZ/2MR | 260 |
Number of patients who are TB LJ culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks
Intervention | participants who are culture negative (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 352 |
Regimen 2 - 2MHRZ/2MHR | 394 |
Regimen 3 - 2EMRZ/2MR | 401 |
The number of participants includes all patients who had at least one grade 3 or 4 adverse event. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)
Intervention | participants with Grade 3 or 4 AEs (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 123 |
Regimen 2 - 2MHRZ/2MHR | 127 |
Regimen 3 - 2EMRZ/2MR | 111 |
"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Favorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months
Intervention | participants with unfavorable outcome (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 87 |
Regimen 2 - 2MHRZ/2MHR | 132 |
Regimen 3 - 2EMRZ/2MR | 132 |
"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Unfavorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months
Intervention | participants with unfavorable outcome (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 172 |
Regimen 2 - 2MHRZ/2MHR | 219 |
Regimen 3 - 2EMRZ/2MR | 217 |
Culture negative for TB using LJ cultures. (NCT00864383)
Timeframe: 18 months
Intervention | Time to culture negative status / weeks (Median) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 6.0 |
Regimen 2 - 2MHRZ/2MHR | 6.0 |
Regimen 3 - 2EMRZ/2MR | 6.0 |
(NCT00864383)
Timeframe: 18 months
Intervention | Time to culture negative status / weeks (Median) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 11.9 |
Regimen 2 - 2MHRZ/2MHR | 8.0 |
Regimen 3 - 2EMRZ/2MR | 8.0 |
Estimation of the lower bound of a one-sided 95% confidence interval of the difference in success rates between arms B and C. If the lower bound is greater than -7%, this will be evidence that the treatment-shortening arm is not inferior to the standard duration arm. (NCT02821832)
Timeframe: 18 months
Intervention | Participants (Count of Participants) | ||||
---|---|---|---|---|---|
Cured | Confirmed relapses | Late withdrawal, lost to follow-up | Probable relapses | Treatment Failure | |
Arm A | 217 | 5 | 13 | 1 | 1 |
Arm B | 121 | 1 | 9 | 1 | 0 |
Arm C | 117 | 9 | 6 | 3 | 4 |
1 review available for pyrazinamide and AIDS Seroconversion
Article | Year |
---|---|
Failure of therapy for tuberculosis in human immunodeficiency virus infection.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Drug Therapy, Combi | 1992 |
5 trials available for pyrazinamide and AIDS Seroconversion
Article | Year |
---|---|
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; HIV Seropositivity; Humans; Incidence; Isoniazid; | 2019 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, C | 2014 |
Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.
Topics: Adult; Aged; Ciprofloxacin; Drug Therapy, Combination; Ethambutol; Female; HIV Seropositivity; HIV-1 | 1993 |
Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
Topics: Adolescent; Adult; Africa, Western; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercul | 1995 |
11 other studies available for pyrazinamide and AIDS Seroconversion
Article | Year |
---|---|
Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis.
Topics: Adult; Antitubercular Agents; Brazil; Ethambutol; Female; HIV Seropositivity; Humans; Isoniazid; Mal | 2020 |
An apparently healthy young man with a peculiar-looking chest radiograph.
Topics: Adult; Antibiotics, Antitubercular; Drug Therapy, Combination; Ethambutol; Fever; HIV Seropositivity | 2011 |
Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India.
Topics: Adult; Antitubercular Agents; Communicable Disease Control; Directly Observed Therapy; Enzyme-Linked | 2011 |
Tuberculosis re-treatment outcomes within the public service in Nairobi, Kenya.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 2002 |
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In | 2003 |
Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid.
Topics: Antitubercular Agents; Chemistry, Clinical; Chromatography; Dose-Response Relationship, Drug; Ethamb | 2004 |
Mycobacterial infections in renal allograft recipients.
Topics: Drug Therapy, Combination; Ethambutol; HIV Seropositivity; Humans; Immunosuppressive Agents; Isoniaz | 1993 |
Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Diarrhea; Ethambutol; Female; HIV Infectio | 1997 |
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Drug Admi | 1998 |
Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system--New York, 1991.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma | 1992 |
From the Centers for Disease Control. Transmission of multidrug-resistant tuberculosis among immunocompromised persons, correctional system--New York, 1991.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma | 1992 |